Key result
Urinary π-GST levels at 3 hours post-surgery significantly predicted the composite outcome of advanced acute kidney injury or in-hospital mortality (OR 1.618).
Why the study?
Does urinary π-glutathione S-transferase predict advanced acute kidney injury and in-patient mortality in patients undergoing cardiovascular surgery?
Cohort (n=141)
Yes
Does urinary π-glutathione S-transferase predict advanced acute kidney injury and in-patient mortality in patients undergoing cardiovascular surgery?
Odds Ratio: 1.618 (95% CI 1.135–2.366)
p-value: p=0.009
Urinary π-GST is a promising early biomarker for predicting advanced AKI and hospital mortality after cardiovascular surgery, improving upon standard SOFA score risk stratification.
May aid post-cardiac surgery risk stratification; hypothesis-generating and requires prospective validation before clinical adoption.
Urinary biomarkers augment the diagnosis of acute kidney injury (AKI), with AKI after cardiovascular surgeries being a prototype of prognosis scenario. Glutathione S-transferases (GST) were evaluated as biomarkers of AKI. Urine samples were collected in 141 cardiovascular surgical patients and analyzed for urinary alpha-(α-) and pi-(π-) GSTs. The outcomes of advanced AKI (KDIGO stage 2, 3) and all-cause in-patient mortality, as composite outcome, were recorded. Areas under the receiver operator characteristic (ROC) curves and multivariate generalized additive model (GAM) were applied to predict outcomes. Thirty-eight (26.9%) patients had AKI, while 12 (8.5%) were with advanced AKI. Urinary π-GST differentiated patients with/without advanced AKI or composite outcome after surgery (p < 0.05 by generalized estimating equation). Urinary π-GST predicted advanced AKI at 3 hrs post-surgery (p = 0.033) and composite outcome (p = 0.009), while the corresponding ROC curve had AUC of 0.784 and 0.783. Using GAM, the cutoff value of 14.7 μg/L for π-GST showed the best performance to predict composite outcome. The addition of π-GST to the SOFA score improved risk stratification (total net reclassification index = 0.47). Thus, urinary π-GST levels predict advanced AKI or hospital mortality after cardiovascular surgery and improve in SOFA outcome assessment specific to AKI.
No takes yet. Share an insight, caveat, or question.
Shu et al. (2016) conducted a cohort in Cardiovascular Surgery (n=141). Urinary π-glutathione S-transferase (π-GST) vs. Lower levels of urinary π-GST was evaluated on Composite outcome of advanced AKI (KDIGO stage 2 or 3) or in-hospital mortality (OR 1.618, 95% CI 1.135-2.366, p=0.009). Urinary π-GST levels at 3 hours post-surgery significantly predicted the composite outcome of advanced acute kidney injury or in-hospital mortality (OR 1.618).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: